Endocrine toxicity in cancer patients treated with anti-PD1 immunotherapy (nivolumab or pembrolizumab): A retrospective multicenter study
Latest Information Update: 11 Nov 2021
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cancer
- Focus Adverse reactions
- 01 Oct 2021 Results published in the Endocrine
- 26 Sep 2019 New trial record
- 12 Sep 2019 Results published in the Journal of Endocrinological Investigation